Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Free Webinar - Master Forex Trading Today! Don't Miss Out | Tuesday, June 6, 2023 | 01:00PM EDT Enroll Now
Amarin: Waiting For The FDA
www.investing.com/analysis/amarin:-waiting-for-the-fda-144693
Amarin: Waiting For The FDA
By Edison | Nov 22, 2012 06:44AM ET
Investment summary: Waiting for the FDA
Amarin’s (AMRN) potential blockbuster Vascepa (icosapent ethyl) is ostensibly due to be launched into the large US cardiovascular market in Q113, although how this will be achieved remains unresolved. Uncertainty over Vascepa’s market exclusivity and commercial strategy has weighed on the shares (-30%) since FDA approval in July 2012. Amarin is considering a trade sale, securing a partner or going it alone as the commercial option for Vascepa. The imminent FDA decision (expected in Dec 12) on Vascepa’s NCE status is a major potential catalyst and could set the shares on a new trajectory, although multiple FDA delays to this verdict do not bode well.
Vascepa could be a game changer
Vascepa (is an omega-3 fatty acid approved in the US as an adjunct therapy to reduce triglycerides (TG) in patients with very high TG levels. Launch is expected in Q113 and will compete against GSK’s omega-3 product Lovaza, with FY12 sales run-rate c $1bn. Vascepa also reduces LDL while Lovaza raises it. Based on this favourable profile, Vascepa could ultimately generate >$1bn in sales.
Vascepa patents are positive, but NCE status is the focus
Amarin has nine issued and allowed patents (+30 pending) for Vascepa that extend its US patent protection out to 2030. However, as the market is unsure whether these patents would be upheld if challenged, Vascepa’s new chemical entity (NCE) status has taken on new importance. If the FDA grants NCE status, Amarin would get at least five years of market exclusivity (only three years if not). The FDA previously delayed its NCE decision, which is now expected in December.
Multiple commercialisation options
Amarin’s options include launching Vascepa itself (with some third-party support), through a partnership with a larger pharma company (which would likely drive greater utilisation) or it may sell itself to another company. The outcome of the FDA’s NCE decision for Vascepa will largely determine how Amarin moves forward.
Valuation: Several near-term catalysts lie ahead
Amarin has an EV of c $1.5bn, reflective of the market’s high expectations for Vascepa. Near-term upside could come from a positive FDA NCE decision and subsequent partnering/acquisition. Downside would come from negative NCE news and/or Amarin launching on its own, putting pressure on its $215m cash reserves.
To Read the Entire Report Please Click on the pdf File Below.
Amarin’s (AMRN) potential blockbuster Vascepa (icosapent ethyl) is ostensibly due to be launched into the large US cardiovascular market in Q113, although how this will be achieved remains unresolved. Uncertainty over Vascepa’s market exclusivity and commercial strategy has weighed on the shares (-30%) since FDA approval in July 2012. Amarin is considering a trade sale, securing a partner or going it alone as the commercial option for Vascepa. The imminent FDA decision (expected in Dec 12) on Vascepa’s NCE status is a major potential catalyst and could set the shares on a new trajectory, although multiple FDA delays to this verdict do not bode well.
Vascepa could be a game changer
Vascepa (is an omega-3 fatty acid approved in the US as an adjunct therapy to reduce triglycerides (TG) in patients with very high TG levels. Launch is expected in Q113 and will compete against GSK’s omega-3 product Lovaza, with FY12 sales run-rate c $1bn. Vascepa also reduces LDL while Lovaza raises it. Based on this favourable profile, Vascepa could ultimately generate >$1bn in sales.
Vascepa patents are positive, but NCE status is the focus
Amarin has nine issued and allowed patents (+30 pending) for Vascepa that extend its US patent protection out to 2030. However, as the market is unsure whether these patents would be upheld if challenged, Vascepa’s new chemical entity (NCE) status has taken on new importance. If the FDA grants NCE status, Amarin would get at least five years of market exclusivity (only three years if not). The FDA previously delayed its NCE decision, which is now expected in December.
Multiple commercialisation options
Amarin’s options include launching Vascepa itself (with some third-party support), through a partnership with a larger pharma company (which would likely drive greater utilisation) or it may sell itself to another company. The outcome of the FDA’s NCE decision for Vascepa will largely determine how Amarin moves forward.
Valuation: Several near-term catalysts lie ahead
Amarin has an EV of c $1.5bn, reflective of the market’s high expectations for Vascepa. Near-term upside could come from a positive FDA NCE decision and subsequent partnering/acquisition. Downside would come from negative NCE news and/or Amarin launching on its own, putting pressure on its $215m cash reserves.
To Read the Entire Report Please Click on the pdf File Below.
Related Articles
Unraveling the Investment Opportunities Amid 2023's Air Travel Boom
By Frank Holmes - Jun 05, 2023
If current forecasts are accurate, this summer could mark a historic high in airline passenger volumes. The industry group Airlines for America (A4A) predicts that approximately...
3 Stocks to Hedge Against a Possible Market Reversal
By Thomas Monteiro/Investing.com - Jun 05, 2023
8
Caution is advised for retail investors amid the current market breakout Weak market breadth, decelerating earnings, and high valuations of tech mega-cap companies indicate a...
Can Bulls Achieve Escape Velocity?
By Michael Kramer - Jun 05, 2023
8
The S&P 500 moved above the resistance zone I have been watching at 4,200 to 4,225. No breakout is complete unless it is confirmed, and for that to happen, you don’t want...
Amarin: Waiting For The FDA
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.